Genomics & Genetics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Resistance
Paclitaxel resistance in ovarian cancer patients likely multifactorial
July 30th, 2004
More than one molecular mechanism likely accounts for paclitaxel resistance in ovarian cancer patients, suggests a study from Italy. "Paclitaxel (PTX) is a potent anti-neoplastic agent that is highly effective in treating ovarian cancer. Nevertheless, the emergence of PTX resistance has limited the control of this disease. To gain insight into the molecular alterations accompanying drug resistance in ovarian cancer, we generated a new stable PTX-resistant ovarian carcinoma cell line," reported S. Violini and colleagues, University of Aquila. "CABA I cells, which display an intrinsic PTX resistance (IC50 = 800 ng/ml), were subjected to...
Source: Genomics & Genetics Weekly (2004-07-30)
|
